Pillai Rajiv, Wang Duolao, Mayer Erik K, Abel Paul
Department of Urology, West Suffolk Hospital, Cambridge University Teaching Hospitals Trust, Suffolk, U.K.
ScientificWorldJournal. 2011 Apr 5;11:751-9. doi: 10.1100/tsw.2011.77.
A risk calculator algorithm to allow prediction of probabilities of 1- and 5-year recurrence and progression rates in individuals with pTa/pT1 bladder cancer has been proposed by the European Organisation for Research and Treatment of Cancer (EORTC) and was incorporated into the European Association of Urology guidelines in 2006. We attempted to validate this algorithm in a cohort of patients with known outcome. Prognostic data were collected from a consecutively presenting cohort of 109 patients with non-muscle invasive (pTa/pT1) transitional cell cancer (TCC) at a single institution between 1983 and 1985. Using the same statistical models as in the EORTC original paper, predicted probabilities of 1- and 5-year recurrence and progression were calculated. Patients were divided into four risk groups for recurrence (Ir-IVr) and progression (Ip-IVp), respectively, using six prognostic criteria. These were then compared to the probabilities predicted in the EORTC algorithm. The predicted 1- and 5-year probabilities of recurrence were significantly higher in the study population as compared to the original EORTC algorithm for all four risk groups. The predicted 1-year probabilities for progression in groups Ip/IIIp and at 5-years for groups Ip/IIp were in accordance with the original algorithm, but were higher for the other progression groups. The concordance for the model of prediction using the study group for recurrence at 1 and 5 years was 62 and 63%, respectively, and for progression was 65 and 67%, respectively. We were unable to validate the proposed algorithm in our group of patients. Although our study has limitations that prevent firm conclusions on the validity of the algorithm, it does expose some of the drawbacks of standardised nomograms when applied to local clinical practice.
欧洲癌症研究与治疗组织(EORTC)提出了一种风险计算器算法,用于预测pTa/pT1期膀胱癌患者1年和5年复发及进展率的概率,并于2006年被纳入欧洲泌尿外科学会指南。我们试图在一组已知预后的患者中验证该算法。1983年至1985年间,在一家机构连续收集了109例非肌层浸润性(pTa/pT1)移行细胞癌(TCC)患者的预后数据。使用与EORTC原始论文相同的统计模型,计算1年和5年复发及进展的预测概率。使用六个预后标准,将患者分别分为复发(Ir-IVr)和进展(Ip-IVp)的四个风险组。然后将这些结果与EORTC算法预测的概率进行比较。与原始EORTC算法相比,研究人群中所有四个风险组的1年和5年复发预测概率均显著更高。Ip/IIIp组的1年进展预测概率和Ip/IIp组的5年进展预测概率与原始算法一致,但其他进展组的预测概率更高。使用研究组进行1年和5年复发预测模型的一致性分别为62%和63%,进展预测的一致性分别为65%和67%。我们无法在我们的患者组中验证所提出的算法。尽管我们的研究存在局限性,无法就该算法的有效性得出确凿结论,但它确实揭示了标准化列线图应用于当地临床实践时的一些缺点。